The purpose of the present study was to examine the roles of signaling pathways potentially activated by TGF␤ (i.e., Smad and p38 mitogen-activated kinase [MAPK]) in regulation of cell migration and proliferation of healing mouse corneal epithelium. METHODS. Activation of Smads or p38MAPK was evaluated by immunohistochemistry in healing mouse corneal epithelium after debridement. The role of endogenous TGF␤ or p38MAPK in epithelial healing was determined in organ-cultured mouse corneas with an epithelial defect, in the presence or absence of a TGF␤-neutralizing antibody or p38MAPK inhibitors, respectively. Cell proliferation was evaluated by incorporation of bromodeoxyuridine. RESULTS. Migrating mouse corneal epithelium had minimal cell proliferation. Smad3 and -4 were found in nuclei of normal corneal epithelium, whereas they were absent in nuclei of migrating cells in association with Smad7 upregulation on epithelial debridement. Administration of TGF␤-neutralizing antibody reduced the protein expression of Smad7 in vivo after a corneal injury. In contrast, phosphorylation and nuclear translocation of p38MAPK were markedly evident in migrating epithelium during healing, but not in uninjured epithelium. In organ culture, addition of p38MAPK inhibitors blocked cell migration more markedly than neutralizing TGF␤-antibody and enhanced cell proliferation in the injured corneal epithelium, in association with phosphorylation of Erk. CONCLUSIONS. Endogenous TGF␤ enhances migration of corneal epithelium during wound healing in mice. The p38MAPK, but not the Smad, cascade plays a major role in promoting cell migration and in suppressing cell proliferation in migrating epithelium. (Invest Ophthalmol Vis Sci.
C orneal epithelial defects must be rapidly resurfaced to avoid microbial infection and further damage to the underlying stroma. Epithelial healing is achieved by migration of the epithelial sheet to cover the denuded surface and enhanced cell proliferation to reestablish the epithelial stratification quickly after resurfacing. It is of interest to note that in the early phase of healing only one of the two cellular responses, cell migration, takes place, whereas cell proliferation is suppressed. 1, 2 Although cell migration promotes rapid reepithelialization, the cessation of cell proliferation may impede healing if such cessation is prolonged.
Various growth factors, including transforming growth factor-␤ (TGF␤), are believed to orchestrate the behavior of healing corneal epithelium: for example, cell migration and proliferation, cell death, and protein synthesis. [3] [4] [5] [6] In mammals, three isoforms of transforming growth factor-␤, (␤1, -2, and -3) are known. Members of TGF␤ family are multifunctional cytokines involved in development, tissue repair, and other physiological or pathologic processes. [7] [8] [9] It has been demonstrated that the TGF␤ isoforms and their receptors are present in corneal and limbal epithelia and other supporting tissues (e.g., conjunctiva and tear fluid). 10 Therefore, it has long been speculated that the TGF␤ isoforms play pivotal roles in maintaining corneal homeostasis in a paracrine and autocrine fashion. [11] [12] [13] [14] [15] TGF␤ is believed to inhibit corneal epithelial cell proliferation in vivo, because it reportedly inhibits cell proliferation of cultured keratinocytes and corneal epithelial cells in vitro. 2,16 -18 This notion is further supported by the observation in which the administration of anti-TGF␤-neutralizing antibodies reduces scar tissue formation in injured corneas 19 and enhances epithelial cell proliferation after a penetrating injury of corneas in mice (Saika S, unpublished observation, 2002) . Recently, Zieske et al. 20 reported that epithelial debridement causes an upregulation of TGF␤ receptor expression on migrating corneal epithelial cells, suggesting that this ligand may have a pivotal role in modulation of functions of migrating corneal epithelial cells during wound healing. However, the exact mechanism by which TGF␤ modulates epithelial cell behavior (cell migration and proliferation) in wound healing remains to be clarified.
In the present study, we examined the roles of signal transduction pathways that can be activated on endogenous TGF␤ stimulation and may regulate epithelial cell migration and proliferation in healing corneal epithelium. To examine whether cell migration may be associated with the suppression of cell proliferation during wound healing, cell proliferation after wounding was determined by incorporation of bromodeoxyuridine (BrdU). Immunohistochemistry was used to determine whether the signaling cascades of Smads and p38MAPK are activated in migrating corneal epithelium after injury. Our data indicate that there was a cessation of cell proliferation and an absence of nuclear Smad3 and -4 in migrating epithelium. In contrast, phosphorylated p38MAPK translocated to nuclei of migrating epithelial cells within 1 hour after debridement. Neutralization of the endogenous TGF␤ isoforms resulted in delay in epithelial resurfacing and reduction in p38MAPK activation in organ-cultured epithelium. Finally, specific p38MAPK inhibitors suppressed cell migration but induced cell proliferation, as well as MAPK-Erk activation, in healing corneal epithelium after debridement in organ culture. In our study, p38MAPK signal, but not Smad, played a major role in promoting cell migration and suppression of cell proliferation, possibly by blocking the MAPK-Erk cascade in healing epithelium after corneal epithelium debridement.
MATERIALS AND METHODS
Animal experiments were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use Committees of Wakayama Medical University and the University of Cincinnati Medical Center.
Epithelial Defect in Mouse Cornea
Adult male C57BL/6J mice (n ϭ 42) were anesthetized by intraperitoneal injection of pentobarbital sodium (70 mg/kg) or combined xylazine (13 mg/kg) and ketamine (87 mg/kg) and topical oxybuprocaine (Santen, Osaka, Japan), and a corneal epithelial debridement (2 mm in diameter) was performed in one eye, as previously reported. 21 The other eye served as the control. Our previous studies have shown that a 2-mm central corneal epithelial debridement is resurfaced in 24 hours. 21 In the current studies, after different periods of injury (1-22 hours), the animals were given BrdU and killed 2 hours later by CO 2 asphyxiation and cervical dislocation, as previously reported. 22 For specimens obtained immediately after epithelial debridement, central corneal epithelium debridement was performed 2 hours after intraperitoneal administration of BrdU, and the experimental animals were killed. Affected eyes from four animals at each time point were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer for 48 hours. Specimens were dehydrated and embedded in paraffin. 22 Affected eyes from three experimental animals were embedded in optimal cutting temperature (OCT) compound (Miles Inc., Elkhart, IN) and subjected to cryosection.
Effect of TGF␤-Neutralizing Antibody on Expression of Smad7 In Vivo
In adult male C57BL/6J mice (n ϭ 34) anesthetized as described earlier, the central cornea of one eye was perforated with a 26-gauge hypodermic needle attached to a micropipette. On puncture, 3 L of neutralizing antibodies against individual and all TGF␤ isoforms in PBS was injected into an eye at the same concentration as previously reported. 21 Nonimmune host IgG at a concentration of 10 g/mL (rabbit or goat; Cappel, ICN Pharmaceuticals, Aurora, OH) was used as the control. The animals were killed at 24 hours, and the enucleated eyes were fixed in 4% paraformaldehyde and subjected to morphologic examination. Paraffin sections from each eye were cut through the central corneal perforation and were immunostained for Smad7, as described later.
Organ Culture of Injured Eyes in the Presence of TGF␤-Neutralizing Antibody or p38MAPK Inhibitors
We examined the effect of a neutralizing anti-TGF␤ antibody or the p38MAPK inhibitors SB202190 and SB203580 on the cell migration and proliferation of corneal epithelial cells. An organ-culture system of debrided corneas was established as previously reported, with a minor modification. 21 An epithelial defect (2 mm in diameter) was created in the center of corneas of 4-week-old C57/BL6 mice under general anesthesia by intraperitoneal injection of pentobarbital sodium. The animals were killed without reawakening, and individual enucleated eyes were then cultured in 1.0 mL of DMEM supplemented with 2.0% fetal bovine serum with either mouse monoclonal anti-TGF␤ (␤1, -2 and -3)-neutralizing antibody (20 g/mL; R & D Systems, Minneapolis, MN) or p38MAPK inhibitors (SB202190 and SB203580; 10 M in 0.5% dimethylsulfoxide; Calbiochem, San Diego, CA), respectively. The control culture contained nonimmune IgG at the same concentration as the neutralizing antibody or 0.5% dimethylsulfoxide, respectively. The closure of the epithelial defect was determined by fluorescein staining after a 2-hour labeling with BrdU after 12, 18, 24, 36, and 48 hours of culture. Four or five eyes were prepared and analyzed for each experimental condition at each time point of the TGF␤ neutralization and the p38 MAPK inhibitors, respectively. Cell proliferation of enucleated eyes was determined with BrdU incubation for 2 hours after the surgery (n ϭ 6 at each time point). Eyes were then fixed in 4% paraformaldehyde after the BrdU-labeling and embedded in paraffin. Deparaffinized sections (5 m thick) were processed for histology and immunostaining for BrdU and phospho-p38MAPK with a mouse monoclonal IgM and IgG anti-phospho-p38MAPK antibody (1:200 or 1:100 dilution in PBS; Santa Cruz Biotechnology, Santa Cruz, CA, and Cell Signaling Technology, Beverly, MA, respectively) in the TGF␤ neutralization experiment and p38MAPK inhibitor experiments, respectively.
Immunohistochemistry
Deparaffinized sections 5 m thick were processed for immunohistochemistry for Smad3, -4, and -7; phosphorylated p38MAPK; and BrdU. After blocking with 3% dry milk and 5% bovine serum in PBS, the sections were incubated with rabbit polyclonal antibody against Smad3 (1:100 dilution in phosphate-buffered saline [PBS]; Zymed, South San Francisco, CA), goat polyclonal antibody against Smad4 (1:200 dilution in PBS; Santa Cruz Biotechnology), Smad7 (1:400 dilution in PBS; Santa Cruz Biotechnology), or mouse monoclonal IgM anti-phospho-p38MAPK antibody (1:200 dilution in PBS) for 12 hours at 4°C. After washes in PBS, the specimens were treated with peroxidase-conjugated antibodies against each immunoglobulin for 4 hours at 4°C. After another wash in PBS, a peroxidase reaction was performed with 3,3Јdiaminobenzidine (DAB), as previously reported. 21, 23 After they were counterstained with methyl green, the sections were mounted in balsam and observed under light microscopy.
Phospho-p38MAPK and phospho-Erk were also detected by immunofluorescent staining. Mouse monoclonal IgG anti-phospho-p38MAPK antibody (1:100 dilution in PBS) and rabbit polyclonal anti-phospho-Erk (1:100 in PBS; Cell Signaling Technology) were allowed to react with specimens overnight at 4°C. After a wash with PBS, they were treated with FITC-conjugated antibodies against each immunoglobulin. FITC was detected under a fluorescence microscope after embedding in a medium containing 4Ј,6Ј-diamino-2-phenylindole (DAPI) nuclear staining dye (VectaShield H-1200; Vector Laboratories, Burlingame, CA).
For BrdU immunostaining, paraffin sections were treated with 2N HCl for 1 hour at 37°C and then washed in PBS before the application of anti-BrdU antibody (11ϫ in PBS; Roche Diagnostics, Mannheim, Germany). Cryosections 7 m thick were processed for immunostaining with goat polyclonal anti-Smad2 antibody (1:200 dilution in PBS; Santa Cruz Biotechnology). These slides were then processed for secondary antibody reaction, DAB reaction and observed under light microscopy. Fig. 1aG ) epithelia, whereas the central resurfacing thin epithelium was still completely lacking BrdU-labeled cells ( Fig. 1aH ). Twentyfour hours after injury, many BrdU-labeled cells were present in the central regenerated epithelium (Fig. 1aK) , and there was a concomitant decrease of BrdU-labeled cells in the limbal-peripheral and midperipheral corneal epithelium (Figs. 1aI, aJ, respectively). We divided the corneal epithelium into five zones: the central zone of 200 m length of the cornea was marked, and the remaining area on each side was then divided into two areas, a midperipheral area and a peripheral area, on each side. The incidence of BrdU-positive cells in these areas was determined and is shown in Figure 1b . Such increased cell proliferation was concomitant with an upregulation of phosphorylation of Erk (Fig. 1c ). Phospho-Erk was faintly detected in the cytoplasm of basal epithelial cells of uninjured epithelium ( Fig. 1cA ) with occasional nuclear localization, but was not detected in migrating corneal epithelial cells 1 ( Fig. 1cC ) and 12 (not shown) hours after debridement. The upregulation of phospho-Erk in the cytoplasm of central epithelial cell was observed at 18 hours (Figs. 1cE). Basal cells were positive for phospho-Erk in the nuclei at 24 hours after debridement ( Fig. 1cG ).
RESULTS

Cell Proliferation and Activation of the Erk-MAP Kinase Cascade in Healing Corneal Epithelium after Epithelial Debridement
Subcellular Distribution of Smad Proteins during Wound Healing of Corneal Epithelium
Smad signaling has been implicated in mediating the inhibition of epithelial cell proliferation induced by TGF␤ in many organs and cell types. 16 -18 First, to examine whether the Smad cascade is activated in migrating epithelial cells, we determined the intracellular distribution of Smad family members during corneal epithelium wound healing after an epithelial debride- Figure 2a shows the results of immunofluorescent staining for Smad3 in healing corneal epithelium. Smad3 protein was detected in almost all the nuclei of epithelial cells in all layers of normal uninjured corneal epithelium, although the intensity of immunoreactivity varied considerably among the nuclei (Fig.  2aA ). These observations suggest that constitutive TGF␤ signaling through the Smad pathway exists in normal corneal epithelium. This constitutive TGF␤ signaling is probably required for the maintenance of corneal epithelium homeostasis. At 6 ( Fig. 2aB ) and 12 (not shown) hours after injury, migrating corneal epithelial cells showed no nuclear Smad3 staining, but the cytoplasm showed prominent staining for Smad3. Eighteen hours after injury, positive nuclear Smad3 staining reappeared in double-layered epithelium that had resurfaced the denuded cornea ( Fig. 2aC ). At 24 hours, nuclear Smad3 staining was again observed in all cells of the regenerated stratified central corneal epithelium (Fig. 2aD ). Anti-Smad3 antibody labeling of nuclei of peripheral epithelium was present during healing intervals lasting from 0 to 24 hours (data not shown). Nonimmune control IgG did not label the corneas (data not shown). Subcellular localization of Smad2 (data not shown) and Smad3 in the corneal epithelium was similar to one another. In Figure  2b , the intracellular localization of Smad4 exhibited a similar pattern to Smad3 during corneal wound healing as shown in Smad7, an inhibitory Smad, inhibits the dimerization and nuclear translocation of Smad3 and -4 and blocks TGF␤ signaling. 16 -18 To determine whether the disappearance of Smad3 and -4 in the nuclei of migrating cells is associated with upregulation of Smad7, the expression pattern of Smad7 protein in healing epithelium was examined by immunohistochemistry (Fig 2c) . In uninjured corneal epithelium ( Fig. 2cA ) and in corneal epithelium immediately after debridement (not shown) Smad7 protein was very weakly detected in the epithelial cell cytoplasm. At 6 ( Fig. 2cB) and 12 (Fig. 2cC ) hours after debridement, the cytoplasm of epithelial cells around the defect exhibited marked immunoreactivity to Smad7. Eighteen (not shown) to 24 hours after injury, the immunoreactivity to Smad7 returned to its basal level, as seen in uninjured corneas (Fig. 2cD ). To elucidate further the mechanism of upregulation of Smad7 on injury and its association with the loss of Smad3 and -4 nuclear localization in migrating epithelial cells, the expression patterns of Smad7 were determined in injured epithelium in the presence or absence of neutralizing anti-TGF␤ antibodies (Fig. 2d ). Smad7 protein expression was upregulated over the entire epithelium after a penetrating injury of cornea with control PBS injection (Figs. 2dA-C). Administration of neutralizing antibodies against TGF␤1 (not illustrated), TGF␤2 (Figs. 2dD-F), and pan anti-TGF␤ antibodies (data not shown) reduced Smad7 expression in the central and midperipheral, but not in the peripheral, epithelium, indicating that both endogenous TGF␤1 and -2 are the factors responsible for Smad7 upregulation in injured epithelium.
Loss of nuclear localization of Smad3 and -4 in migrating corneal epithelial cells implies that Smad signaling may not be directly involved in eliciting cell movement and inhibiting epithelial cell proliferation of migrating cells. This notion prompted us to hypothesize that such cellular behavior in migrating epithelium may be mediated by signaling pathways other than Smads (e.g., p38MAPK cascade).
Phosphorylated p38MAPK in Corneal Epithelium
To examine the possibility that activation of the p38MAPK cascade may mediate the cell migration and suppression of cell proliferation during corneal epithelial wound healing, subcellular localization of phosphorylated p38MAPK was first determined by immunofluorescent staining with an anti-phospho-p38MAPK antibody. As shown in Figure 3 , nuclear translocation of phospho-p38MAPK was detected in the healing corneal epithelium weakly, but positively, as early as 1 hour (Fig. 3B ) and lasted until 24 hours (Fig. 3F) after injury, whereas cells of uninjured epithelium had phospho-p38MAPK mainly in the cytoplasm (Fig. 3A) . Prominent accumulation of phospho-p38MAPK were identified in nuclei of migrating epithelial cells at 6 ( Fig. 3D ) and 12 (Fig. 3E) hours. At 18 (not shown) and 24 (Fig. 3F ) hours after injury it was observed in both the nuclei and cytoplasm of regenerated epithelium. This finding promoted us to hypothesize that signaling mediated by p38MAPK has a major role in regulating cell behavior in healing epithelium.
Organ-Culture with a TGF␤-Neutralizing Antibody
To determine whether corneal epithelial healing is regulated by endogenous TGF␤ through p38MAPK activation, neutralizing antibodies against TGF␤1, -2, and -3 were included in an ex vivo corneal epithelial healing model of cultured eyes (Fig. 4) . The results show that the antibodies delayed the reepithelialization (Fig. 4a ). BrdU-labeled cells were absent in migrating epithelium in control cultures (Figs. 4cA, cC) , whereas several BrdU-labeled cells were seen in migrating epithelium of anti-TGF␤-antibody-treated corneas (Figs. 4cB, cD) . Immunofluorescent staining (Fig. 4d ) showed marked positive immunoreactivity for phospho-p38MAPK, mainly in basal cells of migrating epithelium in control specimens at each culture interval (Fig. 4dA ), whereas staining for phospho-p38MAPK was very faint in corneal epithelium treated with TGF␤-neutralizing antibody (Fig. 4dB ). These observations support the notion that endogenous TGF␤ is one of the cytokines mediating p38MAPK activation, resulting in increases in cell migration and suppression of cell proliferation.
Organ Culture with p38MAPK Inhibitors
The results of organ-culture experiments revealed that endogenous TGF␤ activates p38MAPK and modulates corneal epithelial wound healing. To further confirm this notion, the specific p38MAPK inhibitors SB202190 and SB203580 were added to the medium in an ex vivo wound healing model of cultured mouse eyes. The results show that SB202190 markedly delayed reepithelialization ( Fig. 5 ). Its presence delayed resurfacing of epithelial defects (Figs. 5aF-I, b), compared with control cultures (Figs. 5aA-E, b). In the presence of SB202190, the corneal epithelial defect persisted at 48 hours in the inhibitor-treated culture (Figs. 5aI, b) , whereas all five corneas were resurfaced within 36 hours (Figs. 5aD, b) in the control experiment. The addition of SB202190 produced more profound inhibitory effects on epithelial cell migration than that by the TGF␤-neutralizing antibody.
Histology of control experiments showed that the epithelium sheet started to migrate on the denuded central cornea at 12 hours and that the defect was resurfaced by a single-layered epithelium within 36 hours (Figs. 5cF, cH, cJ) . In contrast, in the presence of SB202190, the edge of the epithelium remained multilayered (stratified) up to 24 hours in culture (Figs. 5cC, cE, cG) resembling that seen at the 0 time point (Fig.  5cA) , and the epithelial migration was noted with a single-celllayered epithelium at the leading edge after 48 hours in culture (Figs. 5cG, cI, cK) . Figure 5d shows the lack of p38MAPK activation in healing epithelium in the presence of SB202190. Figure 6 indicates the status of Erk-MAPK and cell proliferation activity in healing, organ-cultured corneal epithelium in the presence of SB202190. As shown in Figure 1 , epithelial cell proliferation was associated with Erk activation, based on increases in its phosphorylation status, which correlated inversely with p38MAPK phosphorylation. Thus, we examined the effects of a p38MAPK inhibitor on Erk activation in epithelial cells of injured corneas. Figure 6a shows that Erk remained highly phosphorylated in the presence of SB202190 compared with the control. We therefore examined cell proliferation in these specimens by BrdU incorporation (Figs. 6b, 6c ). At the 0 hour time point (incubated with BrdU 2 hours immediately after debridement) in the absence of the inhibitor, no BrdUlabeled cells were found at the edge of the debrided epithelium, whereas in inhibitor-treated specimen BrdU-labeled cells were seen at the same level found in normal uninjured cornea (data not shown). Throughout the culturing period up to 36 hours, BrdU-labeled cells were detected at the margin of the debrided epithelium in the presence of SB202190, with a peak at 18 hours (Figs. 6bB, bD, bF) , while in control culture no BrdU-labeled cells were observed (Fig. 6bA, bC, bE) . The cells of regenerated epithelium resurfacing the denuded cornea reentered the cell cycle at 48 hours in control culture as shown (Fig. 6bG ). Figure 6c summarizes the incidence of BrdU-labeled cells at individual time points. Similar results were obtained with another p38MAPK inhibitor, SB203580 (data not shown). 
DISCUSSION
In the present study in mice, phosphorylation and nuclear translocation of p38MAPK occurred as early as 1 hour after epithelial debridement in vivo and activation of p38MAPK was involved in the stimulation of cell migration and cessation of cell proliferation in healing corneal epithelium after debridement. As for the role of p38MAPK in cell migration, the present study clearly showed that p38MAPK activation is essential for eliciting corneal epithelial cell migration after epithelial debridement by using specific inhibitors. The p38MAPK cascade is reportedly essential for the expression of ␣2 integrin for the migration of cultured keratinocytes, or for the migration-invasiveness of cancer cell lines. 24 -26 In addition, this cascade may be involved in the modulation of cell adhesion through paxillin, which is essential for cell migration. 27 It has been recently demonstrated that TGF␤ mediates p38MAPK activation followed by integrin ␤1 expression leading to epithelial-mesenchymal transition (EMT). 28 EMT is characterized by increased cell mobility and the expression of mesenchymal cell markers (e.g., vimentin or ␣-smooth muscle actin) in association with the loss of epithelial markers (e.g., cadherins) as well as the loss of cell polarity and cell-cell junction. We previously demonstrated that migrating epithelial cells of injured rabbit corneas (i.e., alkali-burn transiently expressed vimentin). 23 These observations imply that corneal epithelial cells may undergo phenotypic changes to gain migratory characteristics in a way similar to the EMT process mediated through activation of the p38MAPK cascade during wound healing.
In our organ culture experiment, adding p38MAPK inhibitors enhanced Erk phosphorylation and induced increases in BrdU incorporation in healing epithelium, indicating that activation of p38MAPK suppresses the MAPK-Erk cascade. The effect of p38MAPK inhibitors on cell proliferation regulation is, Effect of TGF␤-neutralizing antibody on epithelial wound healing and p38MAPK activation. The enucleated eyes with an epithelial defect 2 mm in diameter were organ cultured in the presence or absence of a neutralizing anti-TGF␤ antibody. Epithelial defects were evaluated by fluorescein staining. The antibody delayed the reepithelialization (a, b). In control culture (aA-E), the epithelial defect was resurfaced within 36 hours after debridement, whereas the defect remained, even at 48 hours with the TGF␤-neutralizing antibody. (b) The percentage of remaining defect at each time point indicated in (a). Bar of SD is less than 1.0% at each time point and therefore is obscured. F, control culture; E, TGF␤-neutralizing antibody; **significant at P Ͻ 0.05; ***significant at P Ͻ 0.01. (c) BrdU-labeling of the specimens. Overall, BrdU-labeled cells were not or were very minimally observed in migrating epithelium of the control culture. In contrast, migrating epithelium of antibody-treated cornea contained many BrdU-labeled cells (arrows) at12 (cA, cB) and 36 (cC, cD) hours. (d) Expression of phospho-p38 MAPK in healing epithelium, with or without the TGF␤neutralizing antibody. Positive immunoreactivity for phospho-p38MAPK was observed in migrating epithelial cells of control specimens at each culture interval (dA), whereas very weak immunoreactivity was seen in specimens treated with TGF␤-neutralizing antibody (dB). (dC, dD) Nuclear DAPI staining. Bar, 10 m. however, reportedly cell-type dependent-either positive or negative. For example, activation of p38MAPK suppresses cell proliferation of Kaposi's sarcoma cells, 29 chondrocytes, 30 and vascular endothelial cells. 31 This signaling suppresses cell proliferation through expression of the cdk inhibitor p27 kip1 and hypophosphorylation of Rb tumor-suppressor protein in cultured vascular endothelial cells and in some neoplastic cell lines stimulated by activin. 32, 33 However, p38MAPK-independent inhibition of MAPK/Erk may also be involved in cessation of cell proliferation in migrating epithelium. For example, in some pancreatic carcinoma cell lines, TGF activates a serinethreonine phosphatase that suppresses the growth-factor-dependent MAPK/Erk cascade by dephosphorylating Erk2. 34 Similarly, in macrophages it has been shown that activation of TGF␤-linked Smad signaling leads to downregulation of p38 by inducing MAPK phosphatase-1. 35 Cells in regenerated central corneal epithelium reenter the cell cycle at 24 hours with nuclear translocation of phospho-Erk after epithelial debridement, although phospho-p38MAPK is also detected in the cell nuclei at relatively higher levels at that time point than that in uninjured epithelium. This finding suggests that MAPK-Erk cascade may overcome proliferation inhibition by phosphorylated p38MAPK in regenerated corneal epithelium at this time point.
It has been suggested that Smads may mediate TGF␤ signaling resulting in inhibition of cell proliferation. 16 -18,36 -38 On the contrary, in our results there was a lack of Smad3 and -4 localization in nuclei of migrating corneal epithelial cells after wounding in vivo, which suggests that TGF␤-Smad signaling may not be directly involved in regulation of cell proliferation and migration in mouse corneal epithelium. In addition, Smads were localized in nuclei of uninjured corneal epithelium and restratified epithelium 24 hours after debridement, concomitant with the detection of BrdU-labeled epithelial cells, suggest-FIGURE 5. Effects of a p38MAPK inhibitor on epithelial wound healing and p38MAPK activation. (a) Closure of epithelial defects were examined in organ culture, with and without the p38MAPK inhibitor SB202190 (10 M), as in the TGF␤-neutralization experiment. Defect closure was markedly delayed in the test culture (aF-I) compared with the control culture (aA-E). The epithelial defect was gradually resurfaced at 24 hours after injury in control (aC), but the defect remained the same as the original in the presence of the inhibitor (aG). At this time point the defect in the control culture (aC) was obviously smaller than that in the test culture with the inhibitor (aG). At 36 (aD) and 48 (aE) hours after injury, no defect was observed in all the specimens examined in the control culture, whereas more than 50% of the defect was not resurfaced at these time points in the test culture. (b) The percentage of the defect area remaining. Bar showing standard deviation is less than 1.0% at each time point and therefore is obscured. F, control culture; E, with the inhibitor; **significant at P Ͻ 0.05; ***significant at P Ͻ 0.01. (c) Histology of healing cornea. Organ-cultured mouse eye globes as shown in (a) were subjected to histologic examination by hematoxylin and eosin staining. Immediately after epithelial debridement, disruption of the stratified epithelium was observed (cA). At 12 hours after, the epithelial cells had begun migrating in a single cell-layered epithelial sheet toward the center of the defect in control culture (cB), but in the medium containing the inhibitor SB202190, the epithelium had not started to migrate, and the edge of the wounded epithelium was similar to the original injured epithelium immediately after the debridement (cC). The single cell-layered epithelium migrated to resurface the defect in 24 hours in control cultures (cD) and had completely resurfaced the defect at 36 hours after injury (cF), whereas in the presence of the inhibitor the wounded edge of the epithelium was still multilayered at 24 hours after injury (cE) and two-cell-layered at the leading edge at 36 hours after injury (cG). At 48 hours, the central cornea was resurfaced by a single-cell-layered epithelium (cH) similar to that at 36 hours in the control; whereas, at this time point, the defect remained in culture with the inhibitor (cI). At a higher magnification (cJ and cK), a single-cell-layered epithelium (boxed area in cH) covered the central cornea in the control, whereas single-cell-layered migrating epithelium (boxed area in cI) was observed at the wounded edge in the presence of the inhibitor. (d) Phospho-p38MAPK was not present in epithelium in the specimens organ cultured with the inhibitor. Marked immunoreactivity for phospho-p38MAPK was present in the epithelia in control cultures, but not in those with the inhibitor (dA, dB, at 18 hours). 39 signaling mechanisms regulating cell proliferation may differ in epidermis and corneal epithelium. Our results in the experiment using the TGF␤-neutralizing antibody demonstrated that endogenous TGF␤ is an important intrinsic factor involved in activation of p38MAPK, as well as cell migration, in injured corneal epithelium. Multiple signaling cascades are activated on TGF␤ binding to its cognate receptor-that is, Smads, 40 RhoA-related signals, 41 MAPK-Erk-1/2, 38 stress kinases (i.e., JNK), 42, 43 p38MAPK, 26, 33 phosphatase2A, 44 or PI3-kinase/AKT. 45, 46 Thus, TGF␤ can lead to great variations in cellular response, depending on which of these signaling transduction pathways are within a given cell type. 7, 17 For example, pathways containing Smad, Rho proteins, and PI3kinase are involved in cell differentiation-dedifferentiation, whereas the MAPK-Erk pathway modulates cell proliferation and cell survival. 7,17,41 Although the present study shows that TGF␤ is one of the factors regulating corneal epithelial healing through p38MAPK activation, many other growth factors and cytokines are capable of modulating corneal epithelial cell behavior. Wilson et al. 5 demonstrated that epithelial debridement causes release of IL-1 by the injured cornea, which subsequently induces the expression of hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF) by keratocytes that serve as paracrine modulators of corneal epithelial cells. 47, 48 Moreover, it has been reported recently in cultured corneal epithelial cells that p38MAPK is activated by exogenous addition of HGF or KGF, which results in stimulation of cellular migration. 49 In the same study, however, it was also reported that inhibition of p38MAPK activation enhanced EGF and KGF stimulation of Erk-1/2 activity and proliferation. 49 These in vitro results are consistent with our observation that after wounding of organcultured corneas, p38MAPK inhibition resulted in stimulation of cell proliferation and enhanced MAPK-Erk phosphorylation. Indeed, besides TGF␤, other growth factors (e.g., HGF and KGF), stress kinases, and inflammatory cytokines are presumably involved in the cascade of p38MAPK activation in vivo. 30, 33, 46, 50 A recent study by other investigators showed that HGF augments migration of cultured corneal epithelial cells by using the MAPK-Erk pathway. 51 In a series of our ex vivo corneal wound-healing studies with organ-cultured eyes, we have observed that the MEK inhibitors U0126 and PD98059 do not significantly alter the resurfacing rate of a corneal epithelial defect (data not shown), an observation consistent with the suggestion that the MAPK-Erk pathway does not have a significant role in epithelial cell migration in situ. Because our ex vivo wound-healing model of organ culture mimics the in vivo condition, it is postulated that the MAPK-Erk pathway may differentially regulate migration of corneal epithelial cells between in vitro and in situ/in vivo conditions.
